LifeVantage Corp
NASDAQ:LFVN
LifeVantage Corp
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The company is headquartered in Lehi, Utah and currently employs 160 full-time employees. The company went IPO on 2012-09-12. Its products include Protandim, LifeVantage Omega+, ProBio and Daily Wellness dietary supplements, TrueScience, Axio and PhysIQ. LifeVantage Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. ProBio is a dietary supplement designed to support optimal digestion and immune system function. Daily Wellness is a dietary supplement designed to support and strengthen immune health. TrueScience, which consists of facial cleanser, perfecting lotion, eye serum. PhysIQ, which consists of fat burn, prebiotic and whey protein.
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The company is headquartered in Lehi, Utah and currently employs 160 full-time employees. The company went IPO on 2012-09-12. Its products include Protandim, LifeVantage Omega+, ProBio and Daily Wellness dietary supplements, TrueScience, Axio and PhysIQ. LifeVantage Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3 to support cognitive health, cardiovascular health, skin health, and the immune system. ProBio is a dietary supplement designed to support optimal digestion and immune system function. Daily Wellness is a dietary supplement designed to support and strengthen immune health. TrueScience, which consists of facial cleanser, perfecting lotion, eye serum. PhysIQ, which consists of fat burn, prebiotic and whey protein.
Revenue: Net revenue was $47.6 million, up 0.7% year-over-year, described as a fractionally higher but seasonally low quarter.
LoveBiome Acquisition: The company closed its acquisition of LoveBiome on October 1, which is expected to significantly expand its presence in the gut health supplement market.
Guidance Reaffirmed: Management reiterated full-year revenue guidance of $225 million to $240 million and profitability targets, expecting stronger results in the second half due to the LoveBiome integration and seasonality.
Margins: Gross margin declined 40 basis points to 79.5% due to higher shipping and warehousing costs.
Consultant Community: Integration of LoveBiome’s consultant base was completed swiftly, with strong early engagement and cross-training underway.
Cash Position: Ended the quarter with $13.1 million in cash and no debt, continuing stock buybacks and dividends.
